Navigation Links
Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP).

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 800-561-2601(domestic) or 617-614-3518 (international). The passcode for the conference call is 84510433. A replay of the conference call will be available until August 2, 2007. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 90055877.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forw ard-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,+1-630-754-4352

Web site: http://www.advancedlifesciences.com/

Ticker Symbol: (NASDAQ-NMS:ADLS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... , ... August 07, 2018 , ... Braun Ambulances is ... 8th-10th at Kay Bailey Hutchison Convention Center in Dallas, Texas. Braun Ambulances will have ... and one Liberty model. , Fire Rescue International (FRI) is the International Association ...
(Date:8/3/2018)... ... August 03, 2018 , ... LifeWIRE’s innovative patents in ... of the 5,000-strong association of app companies and information technology firms across the ... Notification Method System and Computer Program Product” and subsequent patents are among those ...
(Date:8/2/2018)... Md. (PRWEB) , ... August 02, 2018 , ... UMD ... up to $7.7 million over 5 years from the National Institute of Allergy and ... tick research program to understand the immune responses of ticks that contribute to the ...
Breaking Medicine Technology:
(Date:8/15/2018)... ... , ... Today David Hyde Apparel debuts the first, fully effective sweat-proof and ... desire for confidence and comfort year-round, the new shirt leverages a patent-pending, double-sided fabric ... most humid of climates. , The brainchild of two recent University of Central Florida ...
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro ... new leadership roles for healthcare executives Simon Frisch and Chris Weinstein, who have ... They assume their roles at a time of tremendous growth for the group, ...
(Date:8/11/2018)... , ... August 10, 2018 , ... Dr. Siavash Eftekhari, ... to Asunción, Paraguay for a week-long international outpost trip to deliver dental care in ... colleagues and support staff, Dr. Eftekhari volunteered his time to help deliver care to ...
(Date:8/9/2018)... , ... August 09, 2018 , ... ... realize their implants have ruptured, according to cross-referenced data from The American Society ... silicone gel implant rupture rates monitored by the FDA. As an MRI is ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... Jim and Kathy Coover and the company’s independent distributors, customers, and employees, the ... 24 hours of fundraising, exceeding the $2 million goal. 100 percent of the ...
Breaking Medicine News(10 mins):